Daihan Pharmaceutical Co.Ltd Total Liabilities
Daihan Pharmaceutical Co.Ltd total liabilities. Based on the latest financial reports, Daihan Pharmaceutical Co.Ltd (023910) has total liabilities worth ₩50.75 Billion KRW (≈ $34.39 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Daihan Pharmaceutical Co.Ltd (023910) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Daihan Pharmaceutical Co.Ltd (2014–2024)
Total liabilities of Daihan Pharmaceutical Co.Ltd from 2014 to 2024. This chart illustrates how Daihan Pharmaceutical Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 023910 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Daihan Pharmaceutical Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Daihan Pharmaceutical Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ester Industries Limited
NSE:ESTER
|
India | Rs8.91 Billion |
|
Scientex Packaging
KLSE:8125
|
Malaysia | RM179.73 Million |
|
HomesToLife Ltd
NASDAQ:HTLM
|
USA | $75.56 Million |
|
Serrano 61 Desarrollo SOCIMI SA
MC:YSRR
|
Spain | €36.97 Million |
|
Caisse Regionale de Credit Agricole Mutuel Loire HauteLoire
PA:CRLO
|
France | €12.54 Billion |
|
Arihant Superstructures Limited
NSE:ARIHANTSUP
|
India | Rs13.20 Billion |
|
Sunfon Construction Co Ltd
TWO:5514
|
Taiwan | NT$3.94 Billion |
|
HELIOS FAIRFAX PARTNERS
F:3UD
|
Germany | €95.85 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Daihan Pharmaceutical Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Daihan Pharmaceutical Co.Ltd total assets.
Liquidity & Leverage Metrics
Daihan Pharmaceutical Co.Ltd Total Liabilities Ratios Explained
Daihan Pharmaceutical Co.Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daihan Pharmaceutical Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daihan Pharmaceutical Co.Ltd (2014–2024)
The table below shows the annual total liabilities of Daihan Pharmaceutical Co.Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩48.42 Billion ≈ $32.81 Million |
+4.62% |
| 2023-12-31 | ₩46.28 Billion ≈ $31.36 Million |
-10.28% |
| 2022-12-31 | ₩51.58 Billion ≈ $34.96 Million |
-26.03% |
| 2021-12-31 | ₩69.73 Billion ≈ $47.26 Million |
-2.01% |
| 2020-12-31 | ₩71.17 Billion ≈ $48.23 Million |
-11.13% |
| 2019-12-31 | ₩80.08 Billion ≈ $54.27 Million |
-15.17% |
| 2018-12-31 | ₩94.39 Billion ≈ $63.97 Million |
+37.75% |
| 2017-12-31 | ₩68.52 Billion ≈ $46.44 Million |
+1.72% |
| 2016-12-31 | ₩67.36 Billion ≈ $45.65 Million |
+8.67% |
| 2015-12-31 | ₩61.99 Billion ≈ $42.01 Million |
-8.19% |
| 2014-12-31 | ₩67.52 Billion ≈ $45.75 Million |
-- |
About Daihan Pharmaceutical Co.Ltd
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.